{
  "meta": {
    "title": "Drugs_Affecting_Blood_Flow",
    "url": "https://brainandscalpel.vercel.app/drugs-affecting-blood-flow-f6057981.html",
    "scrapedAt": "2025-11-29T18:34:04.067Z"
  },
  "questions": [
    {
      "id": 8080,
      "choices": [
        {
          "id": 32288,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intramuscular</span></span></span></p>"
        },
        {
          "id": 32289,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Subcutaneous</span></span></span></p>"
        },
        {
          "id": 32290,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intravenous</span></span></span></p>"
        },
        {
          "id": 32291,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhalational</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old patient, with a history of hypertension and type 2 diabetes, recently underwent total hip replacement surgery. Post-operatively, the healthcare team is focused on preventing venous thromboembolism (VTE), a common complication after such surgeries. Given the patient&#39;s increased risk for VTE due to surgery, immobility, and underlying conditions, the decision to initiate thromboprophylaxis with low molecular weight (LMW) heparin was made. Route of administration of LMW heparin in this patient is</span></span></span></p>",
      "unique_key": "Q1803786",
      "question_audio": null,
      "question_video": null,
      "map_id": 36264,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Subcutaneous</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Low molecular weight (LMW) heparin</strong> is administered <strong>subcutaneously for thromboprophylaxis in post-operative patients.</strong> This route is preferred because it provides a<strong> reliable and consistent absorption,</strong> leading to <strong>predictable anticoagulant effects.</strong> <strong>Subcutaneous </strong>administration is particularly suitable for the<strong> prophylaxis of venous thromboembolism (VTE)</strong> in patients who have <strong>undergone surgeries </strong>such as<strong> total hip replacement, </strong>as it can be given <strong>outside of a hospital setting, does not </strong>require frequent <strong>monitoring of anticoagulation levels</strong>, and has a <strong>lower risk of hematoma</strong> compared to<strong> intramuscular injections.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Intramuscular:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> LMW heparin</strong> is <strong>not </strong>administered <strong>intramuscularly</strong> due to the<strong> risk of hematoma formation in the muscle,</strong> which can be particularly problematic in patients with a<strong> heightened risk of bleeding</strong> or those who are <strong>receiving anticoagulation</strong> <strong>therapy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Intravenous:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While<strong> LMW heparin</strong> can be <strong>administered intravenously,</strong> this route is<strong> not </strong>typically used for <strong>thromboprophylaxis</strong> in the<strong> post-operative setting.</strong> Intravenous administration is more common for <strong>unfractionated heparin,</strong> which requires<strong> monitoring of the anticoagulant effect</strong> and is used in <strong>acute settings.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Inhalational:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This route is<strong> not</strong> <strong>applicable to LMW heparin</strong> as it i<strong>s not designed for inhalation. </strong>The <strong>inhalational</strong> route of administration is used for <strong>drugs</strong> intended to<strong> act directly on the lungs.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to understand the<strong> appropriate route of administration for low molecular weight heparin </strong>in the context of<strong> thromboprophylaxis in post-operative patients</strong>. <strong>Subcutaneous </strong>administration is the<strong> preferred and recommended route </strong>because it offers <strong>consistent absorption and effective prevention </strong>of <strong>VTE without </strong>the need for routine<strong> anticoagulation monitoring</strong>, <strong>minimizing the risk of complications </strong>associated with<strong> other routes of administration.</strong></span></span></span></p>",
      "correct_choice_id": 32289,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8147,
      "choices": [
        {
          "id": 32556,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prostacyclin</span></span></span></p>"
        },
        {
          "id": 32557,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PGF 2&alpha;</span></span></span></p>"
        },
        {
          "id": 32558,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thromboxane A2</span></span></span></p>"
        },
        {
          "id": 32559,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phospholipase C</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Platelet aggregation is blocked by aspirin due to its action on: </span></span></span></p>",
      "unique_key": "Q6662670",
      "question_audio": null,
      "question_video": null,
      "map_id": 36282,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Thromboxane A2</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Aspirin</strong> works by<strong> irreversibly inhibiting the enzyme cyclooxygenase-1 (COX-1) in platelets, </strong>which is crucial for the <strong>synthesis of</strong> <strong>thromboxane A2</strong>, a substance that <strong>stimulates platelets to aggregate</strong> and <strong>arteries to constrict.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong>.<strong> Prostacyclin (PGI2) </strong>is an <strong>anti-aggregatory prostaglandin</strong> produced by <strong>endothelial cells</strong>, and <strong>aspirin </strong>actually helps to<strong> prevent thrombosis</strong> partly by<strong> not</strong> significantly affecting<strong> prostacyclin production.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect. PGF 2&alpha; (Prostaglandin F2 alpha)</strong> is<strong> not</strong> a major target of<strong> aspirin</strong> in the context of <strong>antiplatelet therapy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option D: Incorrect.</strong> <strong>Phospholipase C</strong> is <strong>not</strong> inhibited by<strong> aspirin</strong>; aspirin <strong>targets COX enzymes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Aspirin</strong> <strong>blocks platelet aggregation</strong> by<strong> inhibiting the production of thromboxane A2</strong> through<strong> irreversible acetylation of the COX-1</strong> <strong>enzyme in platelets</strong>, affecting their <strong>function</strong> for the remainder of <strong>their lifespan.</strong></span></span><strong> </strong></span></span></span></p>",
      "correct_choice_id": 32558,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8184,
      "choices": [
        {
          "id": 32704,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Enoxaparin</span></span></span></p>"
        },
        {
          "id": 32705,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Argatroban</span></span></span></p>"
        },
        {
          "id": 32706,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dabigatran</span></span></span></p>"
        },
        {
          "id": 32707,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fondaparinux</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following anticoagulant therapy needs regular monitoring? </span></span></span></p>",
      "unique_key": "Q1909165",
      "question_audio": null,
      "question_video": null,
      "map_id": 36288,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Argatroban</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Argatroban </strong>requires <strong>regular monitoring</strong> because it is a <strong>direct thrombin inhibitor. </strong>It is used in patients with <strong>heparin-induced</strong> <strong>thrombocytopenia (HIT) </strong>and has a <strong>narrow therapeutic window</strong>, meaning the <strong>dosage and therapeutic effect</strong> must be <strong>carefully</strong> <strong>balanced </strong>to <strong>avoid under- or over-anticoagulation</strong>. <strong>Monitoring </strong>is <strong>typically done</strong> using the<strong> activated partial thromboplastin time (aPTT)</strong> to ensure the<strong> drug&#39;s efficacy and safety.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Enoxaparin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Enoxaparin is a<strong> low molecular weight heparin </strong>(LMWH) used for the <strong>prevention and treatment of deep vein</strong> <strong>thrombosis (DVT) and pulmonary embolism (PE).</strong> While it has a <strong>mor</strong>e predictable <strong>dose-response</strong> relationship compared to <strong>unfractionated heparin</strong>, routine<strong> laboratory monitoring </strong>for anticoagulation effect is generally <strong>not required in most patients.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Dabigatran:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Dabigatran is a <strong>direct oral anticoagulant (DOAC)</strong> that<strong> inhibits thrombin.</strong> It is <strong>used </strong>for <strong>stroke prevention</strong> in <strong>non-valvular atrial fibrillation </strong>and<strong> treatment of DVT </strong>and <strong>PE,</strong> among other indications.<strong> Dabigatran</strong> offers the advantage of<strong> fixed dosing without</strong> the need for<strong> routine coagulation monitoring.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Fondaparinux:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Fondaparinux is a <strong>synthetic pentasaccharide</strong> that<strong> inhibits factor Xa indirectly </strong>by <strong>binding to antithrombin</strong>. It is used for<strong> DVT prevention and treatment</strong> and for<strong> preventing PE. Like LMWH, fondaparinux</strong> generally <strong>does not </strong>require <strong>routine</strong> <strong>monitoring</strong> due to its predictable pharmacokinetic profile.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to<strong> understand</strong> which <strong>anticoagulant therapies</strong> require<strong> regular monitoring </strong>and which<strong> does not. </strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture6.jpg\" style=\"height:409px; width:1000px\" /></span></span></p>",
      "correct_choice_id": 32705,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8166,
      "choices": [
        {
          "id": 32632,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dabigatran</span></span></span></p>"
        },
        {
          "id": 32633,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Protamine</span></span></span></p>"
        },
        {
          "id": 32634,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alteplase</span></span></span></p>"
        },
        {
          "id": 32635,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Epsilon aminocaproic acid</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is an antifibrinolytic agent?</span></span></span></p>",
      "unique_key": "Q7148093",
      "question_audio": null,
      "question_video": null,
      "map_id": 36285,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Epsilon aminocaproic acid</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Antifibrinolytic agents </strong>are drugs that help to<strong> prevent the breakdown of blood clots by inhibiting the activity of fibrinolytic enzymes.</strong> <strong>Epsilon aminocaproic acid (EACA) </strong>and<strong> tranexamic acid </strong>are <strong>antifibrinolytic agents </strong>that work by <strong>inhibiting the conversion of</strong> <strong>plasminogen to plasmin, </strong>which is responsible for the <strong>breakdown of fibrin clots.</strong> These are <strong>used to </strong>treat <strong>excessive bleeding</strong> as in <strong>heavy menstrual flow,</strong> in surgical settings, and <strong>to prevent bleeding </strong>in patients <strong>with hemophilia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Dabigatran</strong> is a <strong>direct thrombin inhibitor</strong> that <strong>prevents</strong> the formation of<strong> blood clots</strong> by<strong> inhibiting</strong> the<strong> activity of thrombin,</strong> a key enzyme in the clotting process.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Protamine </strong>is a medication used to <strong>reverse the effects of heparin</strong>. Protamine works by <strong>binding to heparin</strong>,<strong> neutralizing its</strong> <strong>anticoagulant effects.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Alteplase</strong> is a<strong> thrombolytic agent</strong> that works by <strong>converting plasminogen to plasmin, </strong>which <strong>breaks down fibrin clots</strong>. It is used in <strong>cases of acute MI and stroke.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Epsilon aminocaproic acid</strong> and<strong> tranexamic acid </strong>are <strong>antifibrinolytic agents</strong> that <strong>inhibit the conversion of plasminogen to plasmin, preventing the breakdown of fibrin clots.</strong></span></span></span></p>",
      "correct_choice_id": 32635,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8129,
      "choices": [
        {
          "id": 32484,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Filgrastim</span></span></span></p>"
        },
        {
          "id": 32485,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oprelvekin</span></span></span></p>"
        },
        {
          "id": 32486,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Erythropoietin</span></span></span></p>"
        },
        {
          "id": 32487,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Iron dextran</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is given to treat thrombocytopenia secondary to anti-cancer therapy and is known to stimulate progenitor megakaryocytes?</span></span></span></p>",
      "unique_key": "Q3242885",
      "question_audio": null,
      "question_video": null,
      "map_id": 36273,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Oprelvekin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Oprelvekin</strong> is the correct answer because it is a <strong>recombinant form of interleukin-11 (IL-11) </strong>and is specifically used to treat <strong>thrombocytopenia</strong>, which is a d<strong>ecrease in the number of platelets in the blood,</strong> <strong>secondary to anticancer therapy. Oprelvekin</strong> works by <strong>stimulating the proliferation of megakaryocyte progenitor cells</strong>, which are the <strong>precursors to platelets,</strong> thus<strong> increasing platelet</strong> <strong>production</strong>. This mechanism <strong>directly addresses </strong>the condition of<strong> thrombocytopenia</strong> by enhancing the body&#39;s ability to produce <strong>platelets</strong>, making it an<strong> effective treatment </strong>option in this context.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Filgrastim:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Filgrastim is a <strong>granulocyte colony-stimulating factor (G-CSF) </strong>that is used to<strong> increase neutrophil counts</strong> in patients<strong> undergoing chemotherapy.</strong> It <strong>stimulates </strong>the production of<strong> white blood cells,</strong> not platelets, and is therefore <strong>used to treat </strong>or <strong>prevent neutropenia</strong>, not thrombocytopenia.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Erythropoietin:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Erythropoietin is a <strong>glycoprotein hormone</strong> that<strong> stimulates erythropoiesis, </strong>or <strong>red blood cell production,</strong> in the<strong> bone marrow</strong>. It is<strong> used to</strong> treat<strong> anemia,</strong> particularly in<strong> chronic kidney disease </strong>and in patients <strong>undergoing chemotherapy.</strong> It <strong>does not</strong> directly<strong> increase platelet counts.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Iron dextran:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Iron dextran is an<strong> intravenous iron supplement</strong> used to treat <strong>iron deficiency anemia. </strong>It <strong>does not </strong>stimulate the production of <strong>platelets or megakaryocyte progenitors</strong> and is<strong> not used </strong>to treat <strong>thrombocytopenia secondary to anticancer therapy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to understand the<strong> hematopoietic growth factors </strong>and their role in <strong>treatment </strong>options for <strong>adverse effects</strong> of<strong> anticancer drugs</strong>.&nbsp; and to recognize that <strong>oprelvekin</strong> is <strong>used for its ability to stimulate progenitor megakaryocytes</strong>, leading to an <strong>increase in platelet production. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hematopoietic Growth Factors:</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture3.jpg\" style=\"height:543px; width:1000px\" /></span></span></strong></p>",
      "correct_choice_id": 32485,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8207,
      "choices": [
        {
          "id": 32796,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ticlopidine</span></span></span></p>"
        },
        {
          "id": 32797,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tirofiban</span></span></span></p>"
        },
        {
          "id": 32798,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clopidogrel</span></span></span></p>"
        },
        {
          "id": 32799,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prasugrel</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All are ADP inhibitors except:</span></span></span></p>",
      "unique_key": "Q2122889",
      "question_audio": null,
      "question_video": null,
      "map_id": 36263,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Tirofiban</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tirofiban</strong> is<strong> not</strong> an <strong>ADP inhibitor.</strong> It is a <strong>glycoprotein IIb/IIIa inhibitor</strong>, which<strong> prevents fibrinogen</strong> from <strong>binding to platelets,</strong> thereby <strong>inhibiting platelet aggregation. Tirofiban acts</strong> on a<strong> different pathway </strong>in the <strong>platelet aggregation process </strong>compared to <strong>ADP</strong> <strong>inhibitors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Ticlopidine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ticlopidine is an <strong>ADP receptor inhibitor</strong> that <strong>inhibits platelet aggregation</strong> by<strong> blocking the P2Y12 ADP recepto</strong>r on the<strong> platelet surface,</strong> making it <strong>less responsive to stimuli </strong>that cause <strong>aggregation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Clopidogrel:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Clopidogrel </strong>is also an <strong>ADP receptor inhibitor</strong>, similar to ticlopidine, that works by <strong>irreversibly inhibiting</strong> the <strong>P2Y12 subtype of the ADP receptor</strong> on platelets, thus <strong>reducing platelet aggregation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Prasugrel:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Prasugrel is a third example of an <strong>ADP receptor inhibitor.</strong> It is a<strong> prodrug </strong>that, <strong>once metabolized,</strong> <strong>inhibits </strong>the <strong>P2Y12 ADP receptor on platelets</strong>, leading to <strong>decreased platelet aggregation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to <strong>identify the classification of antiplatelet drugs,</strong> specifically distinguishing<strong> ADP receptor inhibitors</strong> <strong>(ticlopidine, clopidogrel, and prasugrel)</strong> from <strong>other classes </strong>such as <strong>glycoprotein IIb/IIIa inhibitors (tirofiban). </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antiplatelet Drugs</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture7.jpg\" style=\"height:500px; width:1000px\" /></p>",
      "correct_choice_id": 32797,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8236,
      "choices": [
        {
          "id": 32911,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Warfarin</span></span></span></p>"
        },
        {
          "id": 32912,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dabigatran</span></span></span></p>"
        },
        {
          "id": 32913,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rivaroxaban</span></span></span></p>"
        },
        {
          "id": 32914,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Heparin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old patient was started on anticoagulant therapy for DVT. Few days after he presented to emergency with the features as shown in figure. Which could be the culprit drug?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture9.jpg\" style=\"height:142px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q6336489",
      "question_audio": null,
      "question_video": null,
      "map_id": 36268,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Warfarin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The figure shows the clinical picture of <strong>dermal vascular necrosis</strong>, also known as<strong> &lsquo;purple toe syndrome.&rsquo;</strong> It is an<strong> early adverse effect</strong> of<strong> warfarin therapy</strong>. This condition is seen in patients with <strong>genetic protein C deficiency.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dermal Vascular Necrosis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Warfarin-induced dermal vascular necrosis </strong>is a<strong> rare </strong>complication of <strong>warfarin therapy</strong>. It is characterized by the development of <strong>painful skin lesions</strong> in patients taking<strong> warfarin. I</strong>t is thought to be <strong>caused by a transient hypercoagulable state</strong> resulting from a<strong> rapid reduction in protein C levels </strong>in patients with<strong> underlying protein C deficiency </strong>or other risk factors. The lesions typically<strong> occur </strong>in areas with a<strong> high concentration of adipose tissue, </strong>such as the<strong> breasts, thighs, and buttocks</strong>. The initial symptoms include <strong>red or purple spots on the skin</strong><strong> </strong>that can<strong> quickly progress to painful, necrotic lesions </strong>with a <strong>central blister </strong>or <strong>eschar.</strong> The<strong> diagnosis </strong>is usually made <strong>clinically</strong> based on the <strong>characteristic appearance of the lesions </strong>and the <strong>patient&#39;s history of</strong> <strong>warfarin therapy.</strong> The treatment of <strong>dermal vascular necrosis</strong> involves<strong> stopping warfarin </strong>and <strong>initiating alternative anticoagulant</strong> therapy, such as <strong>heparin or low molecular weight heparin.</strong> In <strong>severe cases, surgical intervention</strong> may be necessary to<strong> remove</strong> the <strong>necrotic tissue and prevent further damage.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Dabigatran: </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dabigatran is a <strong>direct thrombin inhibitor</strong> and is <strong>not associated with dermal vascular necrosis</strong>. It<strong> does not</strong> <strong>affect protein C levels</strong> or lead to <strong>hypercoagulable states</strong> like<strong> warfarin.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Rivaroxaban: </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rivaroxaban is a<strong> factor Xa inhibitor</strong> and is<strong> not </strong>associated with <strong>dermal vascular necrosis</strong>. Like dabigatran, it <strong>does not </strong>affect<strong> protein C levels</strong> or<strong> lead to hypercoagulable states</strong> like<strong> warfarin.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Heparin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Heparin</strong> is a different class of<strong> anticoagulant </strong>and is <strong>not</strong> associated with <strong>dermal vascular necrosis</strong>. It works by <strong>enhancing the activity of antithrombin III </strong>and<strong> inhibiting </strong>the<strong> coagulation cascade at multiple points.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Warfarin-induced dermal vascular necrosis,</strong> also known as <strong>&#39;purple toe syndrome,&#39;</strong> is a <strong>rare</strong> complication of<strong> warfarin therapy </strong>seen in patients with<strong> genetic protein C deficiency</strong>. <strong>Prompt recognition and management</strong> are <strong>essential to prevent further complications.</strong></span></span></span></span></span></p>",
      "correct_choice_id": 32911,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8140,
      "choices": [
        {
          "id": 32528,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used for the treatment of anaemia due to chronic renal failure.</span></span></span></p>"
        },
        {
          "id": 32529,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It results in decrease in reticulocyte count.</span></span></span></p>"
        },
        {
          "id": 32530,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It decreases the requirement of blood transfusions.</span></span></span></p>"
        },
        {
          "id": 32531,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can cause hypertension.</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements about erythropoietin is false?</span></span></span></p>",
      "unique_key": "Q6468086",
      "question_audio": null,
      "question_video": null,
      "map_id": 36278,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. It results in decrease in reticulocyte count.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Erythropoietin </strong>is a <strong>growth factor</strong> that <strong>stimulates erythropoiesis</strong> or<strong> red blood cell production.</strong> It is indeed used to <strong>treat anaemia</strong>, particularly the type caused by<strong> chronic renal failure</strong>. It should lead to an<strong> <em>increase</em> in reticulocyte count</strong> as it stimulates the <strong>bone</strong> <strong>marrow to produce more red blood cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>&nbsp;Correct.</strong> <strong>Erythropoietin</strong> is used to<strong> treat anaemia</strong> due to <strong>chronic renal failure </strong>because the<strong> kidneys</strong> in such patients <strong>do not</strong> produce enough <strong>endogenous erythropoietin.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Correct.</strong> By <strong>stimulating red blood cell production,</strong> <strong>erythropoietin</strong> <strong>reduces</strong> the need for <strong>blood transfusions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Correct.</strong> <strong>Erythropoietin</strong> can sometimes cause <strong>hypertension </strong>as a <strong>side effect </strong>because of the<strong> increased red blood cell mass</strong> and <strong>possibly</strong> other <strong>mechanisms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Erythropoietin </strong>treatment should result in an <strong>increased reticulocyte count,</strong> reflecting the <strong>stimulated production of red blood cells</strong>. It is <strong>beneficial in chronic renal failure-related anaemia </strong>and can help <strong>decrease </strong>the need for <strong>transfusions,</strong> although it may cause <strong>hypertension </strong>as a<strong> side effect.</strong></span></span></span></p>",
      "correct_choice_id": 32529,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8187,
      "choices": [
        {
          "id": 32716,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is slower acting than clopidogrel.</span></span></span></p>"
        },
        {
          "id": 32717,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is contraindicated in stroke.</span></span></span></p>"
        },
        {
          "id": 32718,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a reversible antagonist of ADP receptors.</span></span></span></p>"
        },
        {
          "id": 32719,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decrease the risk of bleeding.</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements about prasugrel is true as compared to clopidogrel?</span></span></span></p>",
      "unique_key": "Q6614565",
      "question_audio": null,
      "question_video": null,
      "map_id": 36289,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. It is contraindicated in stroke.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Prasugrel </strong>is an <strong>antiplatelet drug</strong> that <strong>inhibits ADP-mediated platelet activation </strong>and <strong>aggregation</strong> by <strong>irreversibly binding to P2Y12</strong> <strong>receptors on platelets. </strong>It is a<strong> thienopyridine</strong> that is converted to <strong>its active metabolite</strong> <strong>more rapidly </strong>than clopidogrel, leading to <strong>more potent and rapid platelet inhibition.</strong> Therefore, <strong>option A is incorrect.</strong> <strong>Prasugrel</strong> is <strong>indicated </strong>for the treatment of <strong>acute</strong> <strong>coronary syndromes (ACS)</strong> and <strong>in patients </strong>undergoing <strong>percutaneous coronary intervention (PCI).</strong> However, it is <strong>contraindicated </strong>in patients with a<strong> history of stroke or transient ischemic attack (TIA) </strong>due to an <strong>increased risk of bleeding</strong>. Therefore, <strong>option B </strong>is the c<strong>orrect answer</strong>. Both prasugrel and clopidogrel <strong>irreversibly</strong> bind to <strong>P2Y12 receptors on platelets,</strong> making them <strong>irreversible</strong> antagonists. Therefore, <strong>option C is incorrect. Prasugrel </strong>has been associated with an <strong>increased risk of bleeding </strong>compared to <strong>clopidogrel</strong>, especially in patients with a<strong> history of stroke or TIA</strong>. Therefore, <strong>option D is</strong> <strong>also incorrect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> It is <strong>slower acting </strong>than clopidogrel:<strong> Prasugrel</strong> is actually <strong>converted to its active metabolite</strong> <strong>more rapidly</strong> than clopidogrel, leading to<strong> more potent </strong>and<strong> rapid platelet inhibition</strong>. Therefore, this statement is<strong> incorrect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> It is a <strong>reversible antagonist</strong> of <strong>ADP receptors:</strong> <strong>Prasugrel, like clopidogrel</strong>, is an<strong> irreversible antagonist </strong>of <strong>ADP receptors on</strong> <strong>platelets</strong>. It forms a <strong>covalent bond with the P2Y12 receptor,</strong> resulting in<strong> irreversible inhibition</strong> of <strong>platelet aggregation. </strong>Thus, this statement is<strong> incorrect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Decrease </strong>the<strong> risk of bleeding</strong>:<strong> Prasugrel</strong> has been associated with an<strong> increased risk of bleeding</strong> compared to <strong>clopidogrel,</strong> especially in <strong>certain patient populations</strong>. Therefore, this statement is<strong> incorrect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Prasugrel </strong>is <strong>contraindicated in patients</strong> with a<strong> history of stroke or transient ischemic attack (TIA) </strong>due to an <strong>increased risk of bleeding.</strong></span></span></span></span></span></p>",
      "correct_choice_id": 32717,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8097,
      "choices": [
        {
          "id": 32356,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Protamine sulphate</span></span></span></p>"
        },
        {
          "id": 32357,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin K</span></span></span></p>"
        },
        {
          "id": 32358,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tranexamic acid</span></span></span></p>"
        },
        {
          "id": 32359,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Factor VIII concentrate</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is used postoperatively to reverse the effect of heparin used intraoperatively in cardiac surgery?</span></span></span></p>",
      "unique_key": "Q3408072",
      "question_audio": null,
      "question_video": null,
      "map_id": 36266,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Protamine sulphate </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Protamine sulphate </strong>is a drug that is used to <strong>neutralize the anticoagulant effects of heparin, </strong>which is a<strong> negatively charged molecule.</strong> <strong>Protamine</strong>, being<strong> positively charged, </strong>binds to<strong> heparin, </strong>forming a <strong>complex that inhibits heparin&#39;s activity,</strong> effectively <strong>reversing its</strong> <strong>effects</strong>. This is particularly important in the <strong>context of cardiac surgery, </strong>where<strong> heparin</strong> is commonly used to<strong> prevent clot formation</strong> <strong>during the procedure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Vitamin K:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong> because<strong> Vitamin K</strong> is used to <strong>reverse the effects of warfarin</strong>, not heparin.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Tranexamic acid:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>as it is used to <strong>reduce bleeding by inhibiting fibrinolysis, </strong>not reversing heparin.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Factor VIII concentrate:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>as it is used in the <strong>treatment of hemophilia A, </strong>not for reversing heparin effects.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Protamine sulphate</strong> is the <strong>drug of choice</strong> for <strong>reversing the anticoagulant effects of heparin</strong> following<strong> cardiac surgeries</strong> or other <strong>procedures </strong>where <strong>heparin has been used</strong>. It works by<strong> binding to and neutralizing heparin.</strong></span></span></span></p>",
      "correct_choice_id": 32356,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8272,
      "choices": [
        {
          "id": 33055,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stop warfarin and start heparin.</span></span></span></p>"
        },
        {
          "id": 33056,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stop warfarin and start heparin plus aspirin.</span></span></span></p>"
        },
        {
          "id": 33057,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Continue warfarin and add heparin.</span></span></span></p>"
        },
        {
          "id": 33058,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Switch to aspirin.</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-week pregnant female was taking warfarin for prosthetic heart valves and has INR value of 3. Next step in the management is? </span></span></span></p>",
      "unique_key": "Q8130860",
      "question_audio": null,
      "question_video": null,
      "map_id": 36281,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Stop warfarin and start heparin.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a <strong>pregnant patient </strong>with a <strong>mechanical heart valve,</strong> <strong>warfarin </strong>poses a <strong>risk to the fetus,</strong> especially in the <strong>first trimester </strong>due to <strong>teratogenicity </strong>and in the <strong>last trimester due to the risk of fetal bleeding.</strong> The approach<strong> close to delivery </strong>is to<strong> switch from warfarin</strong> to <strong>heparin</strong> (either <strong>unfractionated heparin or low molecular weight heparin</strong>), which <strong>does not cross</strong> the <strong>placenta </strong>and therefore<strong> does</strong> <strong>not carry</strong> the same <strong>risks to the fetus.</strong> An<strong> INR of 3</strong> indicates that the patient is<strong> adequately anticoagulated, </strong>but transitioning to <strong>heparin is recommended</strong> as the<strong> patient </strong>approaches term to <strong>reduce the risk of bleeding</strong> <strong>during labor and delivery.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Stop warfarin and start heparin plus aspirin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Aspirin </strong>is an<strong> antiplatelet agent </strong>and is <strong>not </strong>typically required in the context of <strong>prosthetic heart valve </strong>management during pregnancy. Its addition could <strong>increase the risk of bleeding without</strong> providing clear <strong>additional benefit </strong>in this setting.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Continue warfarin and add heparin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Continuing warfarin is<strong> not recommended close to delivery</strong> due to the <strong>risks</strong> mentioned above. The <strong>goal is</strong> to <strong>switch to heparin </strong>solely.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Switch to aspirin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Aspirin</strong> alone is<strong> insufficient</strong> for the management of <strong>thromboembolic risk in patients </strong>with<strong> prosthetic</strong> <strong>heart valves. Anticoagulation with heparin is necessary.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to recognize the<strong> importance of transitioning from warfarin to heparin in pregnant patients</strong> with <strong>mechanical heart valves</strong> as they approach<strong> delivery. Warfarin is contraindicated</strong> close to delivery due to the <strong>risk of fetal hemorrhage,</strong> and<strong> heparin </strong>is the preferred <strong>anticoagulant</strong> because it <strong>does not cross the placenta</strong>. This transition <strong>minimizes the risk of</strong> <strong>thromboembolism </strong>associated with the<strong> prosthetic valve</strong> and <strong>reduces</strong> the potential for <strong>bleeding complications </strong>during <strong>labor and</strong> <strong>delivery.</strong></span></span></p>",
      "correct_choice_id": 33055,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8177,
      "choices": [
        {
          "id": 32676,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Osteophysin</span></span></span></p>"
        },
        {
          "id": 32677,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Osteotensin</span></span></span></p>"
        },
        {
          "id": 32678,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Osteocalcin</span></span></span></p>"
        },
        {
          "id": 32679,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Osteogenin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Warfarin embryopathy is due to the action of? </span></span></span></p>",
      "unique_key": "Q4998383",
      "question_audio": null,
      "question_video": null,
      "map_id": 36286,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Osteocalcin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Warfarin embryopathy </strong>refers to a constellation of<strong> developmental abnormalities </strong>in<strong> fetuses </strong>exposed to<strong> warfarin during pregnancy.</strong> The mechanism underlying <strong>warfarin embryopathy</strong> involves<strong> interference with the vitamin K-dependent carboxylation of osteocalcin,</strong> a<strong> bone matrix protein </strong>crucial for<strong> proper bone development.</strong> <strong>Osteocalcin</strong>, when <strong>carboxylated,</strong> plays a role in<strong> bone</strong> <strong>mineralization and matrix formation</strong>.<strong> Warfarin inhibits</strong> the enzyme <strong>vitamin K epoxide reductase,</strong> leading to <strong>decreased levels of</strong> <strong>reduced vitamin K</strong>, which is necessary for the <strong>carboxylation of osteocalcin. </strong>Consequently, <strong>impaired carboxylation</strong> of<strong> osteocalcin</strong> results in<strong> skeletal abnormalities </strong>characteristic of <strong>warfarin embryopathy,</strong> such as <strong>nasal hypoplasia,</strong> stippled epiphyses, and <strong>long bone deformities.</strong> Thus, the<strong> action of warfarin</strong> causing<strong> embryopathy</strong> is primarily mediated through its <strong>interference with osteocalcin</strong> <strong>carboxylation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Osteophysin: </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">There is<strong> no </strong>known substance called<strong> osteophysin</strong>. It <strong>does not </strong>play a role in<strong> warfarin embryopathy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Osteotensin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Osteotensin</strong> is <strong>not </strong>associated <strong>with warfarin embryopathy.</strong> It is<strong> not</strong> a <strong>recognized factor</strong> involved in<strong> bone</strong> <strong>development</strong> or the <strong>effects of warfarin </strong>on<strong> fetal development.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Osteogenin: </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Osteogenin,</strong> also known as <strong>bone morphogenetic protein-3 (BMP-3),</strong> is a<strong> protein</strong> involved in <strong>bone formation</strong> <strong>and development</strong>. However, it is<strong> not</strong> implicated in the <strong>mechanism of warfarin embryopathy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Warfarin embryopathy</strong> results from the <strong>inhibition of vitamin K-dependent carboxylation of osteocalcin,</strong> a <strong>bone matrix protein</strong> essential for <strong>proper bone development during fetal life.</strong></span></span></p>",
      "correct_choice_id": 32678,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8111,
      "choices": [
        {
          "id": 32412,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alcohol</span></span></span></p>"
        },
        {
          "id": 32413,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phenytoin</span></span></span></p>"
        },
        {
          "id": 32414,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chloroquine</span></span></span></p>"
        },
        {
          "id": 32415,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sulfasalazine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following drugs is least likely to precipitate megaloblastic anaemia in a patient with subclinical folate deficiency?</span></span></span></p>",
      "unique_key": "Q4760285",
      "question_audio": null,
      "question_video": null,
      "map_id": 36270,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Chloroquine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Chloroquine,</strong> an <strong>antimalarial medication</strong>, <strong>does not</strong> interfere with <strong>folate metabolism</strong>, making it the<strong> least likely</strong> of the options provided to precipitate<strong> megaloblastic anemia</strong> in patients with <strong>subclinical folate deficiency.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Chronic alcohol</strong> use can <strong>lead</strong> to various <strong>nutritional deficiencies, </strong>including<strong> folate deficiency, </strong>because of <strong>poor diet,</strong> <strong>malabsorption</strong>, and <strong>ethanol&#39;s</strong> interference with<strong> folate metabolism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Phenytoin,</strong> a widely used <strong>anticonvulsant,</strong> can impair the <strong>absorption of folate </strong>and lead to <strong>megaloblastic anemia,</strong> particularly if <strong>folate reserves</strong> are already<strong> compromised.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Sulfasalazine,</strong> used in the treatment of <strong>inflammatory bowel diseases</strong>, can also <strong>impair folate absorption</strong> and contribute to the <strong>development of megaloblastic anemia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the context of drugs that may<strong> exacerbate or precipitate megaloblastic anemia</strong> due to <strong>folate deficiency</strong>, <strong>chloroquine</strong> is <strong>not</strong> associated with <strong>interference in folate metabolism</strong> and is thus the<strong> least likely </strong>to cause this condition among the options listed.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DRUGS CAUSING MEGALOBLASTIC ANEMIA</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture2.jpg\" style=\"height:527px; width:1000px\" /></span></span></p>",
      "correct_choice_id": 32414,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8158,
      "choices": [
        {
          "id": 32600,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low molecular weight heparin</span></span></span></p>"
        },
        {
          "id": 32601,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antithrombin III inhibitors</span></span></span></p>"
        },
        {
          "id": 32602,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Direct Xa inhibitors</span></span></span></p>"
        },
        {
          "id": 32603,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Warfarin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is commonly used in treatment for cancer associated thromboembolism? </span></span></span></p>",
      "unique_key": "Q4852743",
      "question_audio": null,
      "question_video": null,
      "map_id": 36283,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Low molecular weight heparin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Low molecular weight heparin (LMWH) </strong>is widely used for the<strong> prevention and treatment of thromboembolism</strong>, including in <strong>cancer patients. </strong>It has a<strong> more predictable anticoagulant response </strong>and <strong>doesn&#39;t</strong> require<strong> monitoring,</strong> making it <strong>more convenient for both</strong> <strong>inpatient and outpatient settings.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong>.<strong> Antithrombin III inhibitors aren&#39;t </strong>typically used in the treatment of <strong>thromboembolism;</strong> in fact,<strong> antithrombin</strong> is a<strong> natural inhibitor of coagulation factors</strong>, and<strong> heparins enhance its activity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect. </strong>While <strong>direct Xa inhibitors </strong>are used in the treatment of <strong>thromboembolism</strong>, <strong>LMWH </strong>remains the <strong>standard treatment </strong>for <strong>cancer-associated thrombosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong>. <strong>Warfarin </strong>is used <strong>less frequently in the cancer </strong>population for<strong> thromboembolism </strong>due to the need for<strong> regular monitoring and dose adjustments</strong>, and it<strong> has been surpassed by LMWH </strong>in terms of<strong> efficacy and safety.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Low molecular weight heparin</strong> is the preferred agent for <strong>treating cancer-associated thromboembolism</strong> due to <strong>its efficacy and safety</strong> <strong>profile,</strong> especially <strong>compared to warfarin.</strong></span></span></span></p>",
      "correct_choice_id": 32600,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8255,
      "choices": [
        {
          "id": 32987,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thrombopoietin agonist</span></span></span></p>"
        },
        {
          "id": 32988,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thrombopoietin antagonist</span></span></span></p>"
        },
        {
          "id": 32989,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spleen tyrosine kinase inhibitor</span></span></span></p>"
        },
        {
          "id": 32990,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recombinant IL-11</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old male with a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP) presents with easy bruising and a platelet count of 25,000/&micro;L. He has previously been treated with corticosteroids with temporary improvement in platelet counts. The physician considers adding Eltrombopag for treatment of this patient. What is the mechanism of action of this drug? </span></span></span></p>",
      "unique_key": "Q6805504",
      "question_audio": null,
      "question_video": null,
      "map_id": 36272,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Thrombopoietin agonist </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Eltrombopag</strong> is a <strong>thrombopoietin receptor agonist.</strong> Its<strong> mechanism of action</strong> involves <strong>binding to and activating </strong>the<strong> thrombopoietin</strong> <strong>receptor on the surface of megakaryocytes</strong> and <strong>megakaryocyte precursors</strong> within the <strong>bone marrow. </strong>This <strong>activation </strong>leads to <strong>increased production and maturation of platelets</strong>, making it an <strong>effective treatment for patients </strong>with <strong>chronic idiopathic</strong> <strong>thrombocytopenic purpura (ITP), </strong>who have<strong> low platelet counts </strong>and are <strong>at risk of bleeding.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Thrombopoietin antagonist:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This would be <strong>incorrect</strong> because an <strong>antagonist</strong> would<strong> block</strong> the effect of <strong>thrombopoietin</strong>, which <strong>would not </strong>help to<strong> increase platelet counts </strong>in a patient with ITP.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Spleen tyrosine kinase inhibitor:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>fostamatinib </strong>is an example of a <strong>spleen tyrosine kinase (Syk) inhibitor,</strong> which has a different<strong> mechanism of action</strong>. <strong>Fostamatinib</strong> is <strong>used </strong>in the treatment of<strong> ITP by inhibiting the Syk enzyme</strong>, leading to a <strong>reduction in</strong> the <strong>immune-mediated destruction of platelets.</strong> It<strong> targets</strong> the <strong>signalling pathways</strong> in<strong> immune cells</strong> that are involved in the pathogenesis of <strong>autoimmune diseases</strong> and has been indicated for<strong> adult patients with chronic ITP</strong> who have <strong>not </strong>responded <strong>adequately </strong>to other therapies. Patients on <strong>fostamatinib</strong> are<strong> monitored for side effects </strong>such as <strong>hypertension and liver function</strong> <strong>abnormalities</strong>. <strong>Spleen tyrosine kinase inhibitors</strong> work on <strong>different pathways</strong>,<strong> </strong>typically related to the<strong> immune response,</strong> and <strong>are not</strong> used to<strong> increase platelet production.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Recombinant IL-11:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This option is <strong>incorrect</strong> because <strong>eltrombopag</strong> is<strong> not</strong> a form of<strong> recombinant interleukin-11</strong>, which is another <strong>cytokine</strong> used in different clinical contexts. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Recombinant IL-11</strong>, known as <strong>oprelvekin</strong>, is used to treat<strong> thrombocytopenia,</strong> but it is <strong>not </strong>the drug in question.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to <strong>recognize the mechanism of action of eltrombopag</strong> as a<strong> thrombopoietin receptor agonist</strong>, which is <strong>used to treat thrombocytopenia </strong>in conditions such as<strong> chronic ITP</strong> by <strong>stimulating platelet production </strong>in the bone marrow.</span></span></p>",
      "correct_choice_id": 32987,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8136,
      "choices": [
        {
          "id": 32512,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If 200-300 mg elemental iron is consumed, about 50 mg is absorbed.</span></span></span></p>"
        },
        {
          "id": 32513,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The proportion of iron absorbed reduces as haemoglobin improves.</span></span></span></p>"
        },
        {
          "id": 32514,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The reticulocyte count should begin to increase in two weeks and peak in four weeks - this suggests a good response to treatment.</span></span></span></p>"
        },
        {
          "id": 32515,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The treatment should be discontinued immediately once haemoglobin normalizes to prevent side effects of iron.</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is NOT a characteristic feature of treatment of iron deficiency anaemia with oral iron supplements?</span></span></span></p>",
      "unique_key": "Q5007148",
      "question_audio": null,
      "question_video": null,
      "map_id": 36276,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:16px\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. The treatment should not be discontinued immediately once haemoglobin normalizes to prevent recurrence of iron deficiency anaemia.</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:16px\">The statement &quot;The <strong>treatment</strong> should be<strong> discontinued immediately once hemoglobin normalizes </strong>to prevent<strong> side</strong> <strong>effects of iron&quot;</strong> is<strong> incorrect. Iron supplementation</strong> should continue for an<strong> additional 3-6 months </strong>after<strong> hemoglobin</strong> <strong>levels normalize</strong>. This <strong>extended treatment</strong> ensures that <strong>body iron stores </strong>are <strong>fully replenished,</strong> which helps <strong>prevent</strong> a r<strong>elapse of anemia</strong>. <strong>Stopping</strong> treatment <strong>prematurely</strong> can result in<strong> incomplete iron store replenishment </strong>and a <strong>recurrence of anemia.</strong></span></p>\r\n\r\n<h2><span style=\"font-size:16px\">Explanation of Other Options</span></h2>\r\n\r\n<p><span style=\"font-size:16px\"><strong>A. If 200-300 mg elemental iron is consumed, about 50 mg is absorbed:&nbsp;</strong>This <strong>statement is accurate. </strong>The body typically <strong>absorbs</strong> about <strong>10-20% </strong>of the <strong>elemental iron from oral supplements.</strong> Therefore, from a<strong> dose of 200-300 mg</strong>, approximately <strong>20-60 mg of iron is absorbed.</strong> This amount can <strong>vary depending</strong> on the individual&#39;s <strong>current iron levels </strong>and<strong> overall health.</strong></span></p>\r\n\r\n<p><span style=\"font-size:16px\"><strong>B. The proportion of iron absorbed reduces as hemoglobin improves:&nbsp;</strong>This statement is <strong>correct</strong>. As <strong>iron stores</strong> are<strong> replenished and hemoglobin levels improve</strong>, the<strong> body regulates </strong>and <strong>decreases the absorption efficiency of iron. </strong>This is a <strong>natural feedback </strong>mechanism to <strong>prevent iron overload.</strong></span></p>\r\n\r\n<p><span style=\"font-size:16px\"><strong>C. The reticulocyte count should begin to increase in two weeks and peak in four weeks - this suggests a good response to treatment:&nbsp;</strong>This is a <strong>true statement</strong>. An<strong> increase</strong> in the <strong>reticulocyte count </strong>indicates that the<strong> bone marrow</strong> is responding to<strong> iron</strong> <strong>therapy.</strong> This<strong> increase </strong>typically begins <strong>within 7-10 days</strong> of <strong>starting treatment </strong>and <strong>peaks at around 2-4 weeks,</strong> <strong>reflecting effective erythropoiesis </strong>(production of red blood cells).</span></p>\r\n\r\n<h2><strong><span style=\"font-size:16px\">Educational Objective</span></strong></h2>\r\n\r\n<p><span style=\"font-size:16px\">When treating<strong> iron deficiency anemia</strong> with <strong>oral iron supplements</strong>, it is essential to understand that the <strong>body absorbs</strong> about<strong> 10-20% </strong>of the<strong> elemental iron</strong> from these<strong> supplements</strong>, meaning that from a<strong> dose of 200-300 mg, </strong>around <strong>20-60</strong> <strong>mg</strong> is<strong> absorbed</strong>. As <strong>hemoglobin levels improve,</strong> the <strong>efficiency of iron absorption decreases</strong> due to the body&#39;s <strong>natural regulatory mechanisms</strong> to<strong> prevent iron overload. </strong>An effective response to treatment is indicated by an <strong>increase in reticulocyte count</strong>, typically observed<strong> within 2 weeks</strong> and <strong>peaking at 4 weeks.</strong> Importantly,<strong> iron</strong> <strong>supplementation </strong>should <strong>continue for 3-6 months </strong>after <strong>hemoglobin normalization</strong> to ensure <strong>complete replenishment</strong> of<strong> iron stores</strong> and<strong> prevent</strong> the <strong>recurrence of anemia,</strong> highlighting that <strong>stopping </strong>treatment <strong>immediately</strong> <strong>after normalization</strong> is<strong> incorrect. </strong>Understanding these principles<strong> helps</strong> in the<strong> effective management of iron deficiency</strong> <strong>anemia</strong> and in <strong>preventing its recurrence.</strong></span></p>",
      "correct_choice_id": 32515,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8107,
      "choices": [
        {
          "id": 32396,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clopidogrel</span></span></span></p>"
        },
        {
          "id": 32397,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cephalosporins</span></span></span></p>"
        },
        {
          "id": 32398,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-depressants</span></span></span></p>"
        },
        {
          "id": 32399,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Multivitamins</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A healthy volunteer was taken for a blood donation. A history was taken from the volunteer before the experiment regarding exposure of NSAIDs, which he specifically denied. But on testing, the bleeding time was found to be increased. All the following can be responsible for increase in bleeding time in this person EXCEPT</span></span></span></p>",
      "unique_key": "Q2798642",
      "question_audio": null,
      "question_video": null,
      "map_id": 36267,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Multivitamins </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An <strong>increased bleeding time (BT) </strong>can indicate a defect in<strong> primary hemostasis,</strong> which may be caused by <strong>platelet dysfunction or</strong> <strong>vascular abnormalities.</strong> Multivitamins, typically composed of<strong> vitamins and minerals essential for health, </strong>are<strong> not </strong>known to <strong>affect</strong> <strong>bleeding time</strong> significantly. While <strong>certain nutrients (like vitamin K)</strong> can <strong>impact blood coagulation pathways</strong>,<strong> multivitamins</strong> in <strong>standard dosages</strong> <strong>do no</strong>t adversely affect<strong> platelet function or bleeding time</strong>. Therefore, they are the<strong> least likely </strong>to be responsible for an<strong> increased bleeding time </strong>in a <strong>healthy volunteer </strong>who has denied NSAID use.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Clopidogrel:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Clopidogrel is an<strong> antiplatelet drug that inhibits the P2Y12 ADP receptor on platelets, preventing platelet</strong> <strong>aggregation</strong> and thus can<strong> increase bleeding time</strong>. It is used to<strong> reduce the risk of heart disease </strong>and<strong> stroke</strong> in those at high risk.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Cephalosporins:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Certain <strong>cephalosporins,</strong> especially those with a<strong> methylthiotetrazole (MTT)</strong> side chain (like<strong> cefotetan</strong> and <strong>cefoperazone</strong>), can <strong>interfere with vitamin K metabolism </strong>or have a<strong> direct effect on platelet function</strong>, leading to an<strong> increased risk of</strong> <strong>bleeding</strong>. This makes <strong>cephalosporins a plausible </strong>cause for an<strong> increased bleeding time in individuals</strong> <strong>without</strong> apparent exposure to <strong>NSAIDs.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Anti-depressants:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Some antidepressants, particularly <strong>selective serotonin reuptake inhibitors (SSRIs)</strong>, can <strong>increase</strong> <strong>bleeding time</strong>. SSRIs <strong>increase serotonin levels</strong> in the central nervous system but can also<strong> lead to a reduction in serotonin storage</strong> <strong>within platelets</strong>, which plays a role in<strong> platelet aggregation.</strong> This effect can subtly<strong> increase bleeding time</strong>, making <strong>antidepressants </strong>a possible <strong>cause for the observation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to <strong>recognize substances</strong> that can <strong>affect bleeding time</strong>, with a <strong>specific focus</strong> on understanding that c<strong>ommon multivitamins</strong> <strong>do not </strong>typically cause an<strong> increase in bleeding time.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Important Drugs that can increasing bleeding time</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture1_hSfcgav.jpg\" style=\"height:436px; width:1000px\" /></span></strong></span></span></p>",
      "correct_choice_id": 32399,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8259,
      "choices": [
        {
          "id": 33003,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Protamine sulfate</span></span></span></p>"
        },
        {
          "id": 33004,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin K</span></span></span></p>"
        },
        {
          "id": 33005,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Andexanet &alpha;</span></span></span></p>"
        },
        {
          "id": 33006,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Idarucizumab</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 72-year-old male with a history of non-valvular atrial fibrillation is brought to the emergency department following a minor car accident. He is currently taking dabigatran for stroke prevention. On examination, he has a laceration on his forehead that is bleeding profusely, and his blood tests reveal a prolonged activated partial thromboplastin time (aPTT). Given the acute bleeding and his anticoagulation therapy, the emergency physician decides to administer a specific antidote to reverse the effects of dabigatran. Which of the following medications should be used?</span></span></span></p>",
      "unique_key": "Q7667022",
      "question_audio": null,
      "question_video": null,
      "map_id": 36274,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Idarucizumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Idarucizumab </strong>is a <strong>monoclonal antibody </strong>fragment that is used as a<strong> specific antidote against dabigatran</strong>. It <strong>binds to dabigatran</strong> and <strong>its active metabolites</strong> with <strong>high affinity, neutralizing</strong> their<strong> anticoagulant effect </strong>almost <strong>immediately</strong>. This is particularly useful in <strong>emergency situations </strong>where<strong> rapid reversal of anticoagulation</strong> is<strong> necessary,</strong> such as in the case of <strong>significant bleeding </strong>or when <strong>urgent surgery</strong> is required.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Protamine sulfate:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Protamine sulfate is used to <strong>reverse the effects of heparin,</strong> not direct thrombin inhibitors like dabigatran.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Vitamin K:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Vitamin K is used to <strong>reverse the anticoagulant effects of warfarin,</strong> a<strong> vitamin K antagonist</strong>. It is <strong>not </strong>effective against the<strong> anticoagulant effects of dabigatran.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Andexanet &alpha;:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Andexanet alfa is an <strong>antidote</strong> for the <strong>reversal of the anticoagulant effects of Factor Xa inhibitors</strong>, not direct thrombin inhibitors.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to know the <strong>antidotes of different anti-coagulants </strong>particularly<strong> idarucizumab </strong>as the specific<strong> reversal</strong> <strong>agent for dabigatran</strong>, a <strong>direct thrombin inhibitor. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ANTIDOTES OF ANTI-COAGULANTS</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture13.jpg\" style=\"height:272px; width:1000px\" /></span></span></strong></p>",
      "correct_choice_id": 33006,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8262,
      "choices": [
        {
          "id": 33015,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These interfere with the synthesis of vitamin K dependent clotting factors.</span></span></span></p>"
        },
        {
          "id": 33016,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These can produce anticoagulant effect both in vivo and in vitro.</span></span></span></p>"
        },
        {
          "id": 33017,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These can produce bleeding like hematuria and cerebral hemorrhage.</span></span></span></p>"
        },
        {
          "id": 33018,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Their action starts immediately, so are useful for initiation of therapy in deep vein thrombosis.</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is true regarding the warfarin group of oral anticoagulants?</span></span></span></p>",
      "unique_key": "Q8490239",
      "question_audio": null,
      "question_video": null,
      "map_id": 36275,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. These can produce bleeding like hematuria and cerebral hemorrhage</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Warfarin</strong> group of drugs act by<strong> inhibiting the activation of vitamin K dependent clotting factors.</strong> These factors include <strong>clotting factors II, VII, IX and X. </strong>These <strong>do not inhibit synthesis</strong> of these factors. Therefore option a is<strong> incorrect.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>These interfere with the synthesis of vitamin K dependent clotting factors.</strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>incorrect.</strong> Warfarin and other drugs in its <strong>class inhibit the activation of vitamin K-dependent clotting</strong> <strong>factors</strong> rather than interfering with <strong>their synthesis</strong>. These factors include <strong>II, VII, IX, and X.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>These can produce anticoagulant effect both in vivo and in vitro.</strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is<strong> incorrect</strong>. Warfarin and similar drugs primarily exert their <strong>anticoagulant effects in vivo</strong>, <strong>within the</strong> <strong>body</strong>. They <strong>do not</strong> directly affect <strong>clotting factors outside of the body (in vitro).</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>These can produce bleeding like hematuria and cerebral hemorrhage.</strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true</strong>. Bleeding, including <strong>hematuria (blood in the urine) </strong>and <strong>cerebral hemorrhage (bleeding in the</strong> <strong>brain)</strong>, is a <strong>common adverse effect</strong> of<strong> warfarin and other oral anticoagulants</strong>. This<strong> risk </strong>is particularly relevant when <strong>using</strong> these <strong>medications</strong> due to their <strong>anticoagulant effects.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Their action starts immediately, so are useful for initiation of therapy in deep vein thrombosis.</strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is<strong> incorrect</strong>. The action of<strong> warfarin and similar drugs is delayed</strong>, typically taking <strong>1-3 days </strong>to produce a <strong>therapeutic effect. </strong>Therefore, they are<strong> not useful for the immediate initiation of therapy</strong> in conditions like <strong>deep vein</strong> <strong>thrombosis</strong>, where<strong> more rapid anticoagulation </strong>is <strong>required.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Warfarin and similar oral anticoagulants</strong> primarily exert their <strong>effects in vivo,</strong> can lead to <strong>bleeding complications</strong> such as<strong> hematuria</strong> and <strong>cerebral hemorrhage</strong>, and have a<strong> delayed onset of action,</strong> making them<strong> unsuitable for immediate therapy</strong> initiation in conditions like<strong> deep vein thrombosis.</strong></span></span></span></span></span></p>",
      "correct_choice_id": 33017,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8268,
      "choices": [
        {
          "id": 33039,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clopidogrel</span></span></p>"
        },
        {
          "id": 33040,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prasugrel</span></span></p>"
        },
        {
          "id": 33041,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ticagrelor</span></span></span></p>"
        },
        {
          "id": 33042,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ticlopidine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs reversibly binds the site labelled as B in the given figure?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture14.jpg\" style=\"height:269px; width:300px\" /></p>",
      "unique_key": "Q6485862",
      "question_audio": null,
      "question_video": null,
      "map_id": 36279,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Ticagrelor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The site labelled as<strong> &quot;B&quot; in the figure</strong> represents the <strong>P2Y12 receptor, </strong>a key component in the <strong>activation and aggregation of platelets.</strong> <strong>Ticagrelor</strong> is the <strong>drug</strong> among the options provided that <strong>reversibly binds to the P2Y12 receptor. Unlike clopidogrel, prasugrel, </strong>and <strong>ticlopidine, </strong>which are <strong>thienopyridines and irreversibly inhibit the P2Y12 receptor</strong>,<strong> ticagrelor binds reversibly,</strong> allowing for a<strong> quicker</strong> <strong>recovery of platelet function</strong> upon <strong>discontinuation of the drug.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Clopidogrel:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Clopidogrel<strong> irreversibly binds to the P2Y12 receptor</strong>, <strong>preventing ADP from binding</strong> and thus <strong>inhibiting</strong> <strong>platelet activation and aggregation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Prasugrel:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Prasugrel is another <strong>thienopyridine</strong> that <strong>irreversibly inhibits the P2Y12 receptor,</strong> similar to clopidogrel.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Ticlopidine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ticlopidine was one of the<strong> first thienopyridine drugs to inhibit the P2Y12 receptor irreversibly.</strong> It is <strong>less</strong> <strong>commonly used</strong> now due to<strong> its side effect profile.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to understand the <strong>mechanism of action of P2Y12 inhibitors </strong>and to <strong>differentiate between reversible</strong> and <strong>irreversible inhibition of this receptor</strong>. <strong>Ticagrelor&#39;s ability</strong> to<strong> reversibly bind the P2Y12 receptor</strong> on <strong>platelets distinguishes </strong>it from other <strong>thienopyridine drugs,</strong> which <strong>bind irreversibly,</strong> and has <strong>clinical implications </strong>for the management of patients requiring <strong>antiplatelet therapy.</strong></span></span></p>",
      "correct_choice_id": 33041,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8138,
      "choices": [
        {
          "id": 32520,
          "text": "<p><span style=\"font-size:12pt;\">Tolerable dose will deliver 40 to 60 mg of iron per dose.</span></p>"
        },
        {
          "id": 32521,
          "text": "<p><span style=\"font-size:12pt;\">Mass of total salt is important in determining daily dose.</span></p>"
        },
        {
          "id": 32522,
          "text": "<p><span style=\"font-size:12pt;\">Treatment should be stopped as soon as normal haemoglobin level is reached.</span></p>"
        },
        {
          "id": 32523,
          "text": "<p><span style=\"font-size:12pt;\">Desired rate of haemoglobin improvement is 0.5 mg per day.</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">For oral iron supplements used for iron deficiency anaemia, which of the following statements is correct?</span></p>",
      "unique_key": "Q5389743",
      "question_audio": null,
      "question_video": null,
      "map_id": 36277,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. A. Tolerable dose will deliver 40 to 60 mg of iron per dose.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>For treating iron deficiency anaemia,</strong> a tolerable dose of <strong>oral iron supplements </strong>typically delivers between <strong>40 to 60 mg of elemental</strong> <strong>iron per dose,</strong> which is <strong>adequate to correct anaemia without</strong> causing significant<strong> gastrointestinal side effects.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B:</strong> It is the<strong> mass of elemental iron</strong>, rather than the <strong>mass of total salt</strong>, that is critical in determining the <strong>daily dose,</strong> because the<strong> percentage of elemental iron </strong>varies between <strong>different iron salts.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C:</strong> <strong>Treatment</strong> with <strong>oral iron</strong> should<strong> not be stopped</strong> as soon as <strong>normal haemoglobin level is reached;</strong> it should continue for <strong>several months to replenish iron stores.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D:</strong> The <strong>desired rate of haemoglobin improvement</strong> is usually<strong> 0.5 to 1 g/dL per week,</strong> not per day.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Educational objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">When treating <strong>iron deficiency anaemia,</strong> it's important to consider the <strong>amount of elemental iron in oral supplements </strong>and <strong>continue</strong> <strong>treatment beyond the normalization of haemoglobin</strong> to<strong> fully replenish iron stores.</strong></span></p>",
      "correct_choice_id": 32520,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8087,
      "choices": [
        {
          "id": 32316,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Epsilon Aminocaproic acid</span></span></span></p>"
        },
        {
          "id": 32317,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Protamine</span></span></span></p>"
        },
        {
          "id": 32318,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Heparin</span></span></span></p>"
        },
        {
          "id": 32319,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Streptokinase</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the recommended management for a patient who experiences excessive bleeding after receiving fibrinolytic therapy for an acute myocardial infarction? </span></span></span></p>",
      "unique_key": "Q7026114",
      "question_audio": null,
      "question_video": null,
      "map_id": 36265,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Epsilon Aminocaproic acid</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Epsilon aminocaproic acid (EACA)</strong> is an<strong> antifibrinolytic agent</strong> that acts as a <strong>competitive inhibitor</strong> of <strong>plasminogen activation.</strong> During <strong>fibrinolytic therapy</strong>, agents like<strong> streptokinase</strong> are administered to <strong>dissolve blood clots</strong>. However, if <strong>bleeding becomes excessive,</strong> agents such as<strong> EACA </strong>are used to<strong> inhibit further breakdown of fibrin</strong>, thus<strong> stabilizing existing clots and reducing bleeding.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Protamine:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is<strong> incorrect as protamine</strong> is used to <strong>reverse the effects of heparin,</strong> not fibrinolytic therapy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Heparin:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is<strong> incorrect as heparin </strong>is an<strong> anticoagulant </strong>and would exacerbate bleeding.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Streptokinase:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is <strong>incorrect </strong>as <strong>streptokinase is a fibrinolytic agent</strong>, not an antidote.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Epsilon aminocaproic acid </strong>is used to manage<strong> excessive bleeding by inhibiting fibrinolysis </strong>following <strong>fibrinolytic therapy </strong>in<strong> acute</strong> <strong>myocardial infarction.</strong> It is a <strong>lysine</strong> analog that<strong> prevents plasminogen from binding to fibrin,</strong> thereby <strong>reducing the breakdown of</strong> <strong>fibrin clots.</strong></span></span></span></p>",
      "correct_choice_id": 32316,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8109,
      "choices": [
        {
          "id": 32404,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prasugrel</span></span></span></p>"
        },
        {
          "id": 32405,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ticlopidine</span></span></span></p>"
        },
        {
          "id": 32406,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tirofiban</span></span></span></p>"
        },
        {
          "id": 32407,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vorapaxar</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a antagonist of PAR-1 receptors of thrombin?</span></span></span></p>",
      "unique_key": "Q5091579",
      "question_audio": null,
      "question_video": null,
      "map_id": 36269,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Vorapaxar</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Vorapaxar</strong> is a<strong> novel antiplatelet agent</strong> that works by <strong>antagonizing protease-activated receptor-1 (PAR-1) on platelets.</strong> <strong>Thrombin </strong>is a <strong>potent platelet activator </strong>that works through<strong> PAR-1</strong> to induce<strong> platelet aggregation.</strong> <strong>Vorapaxar&#39;s inhibition of PAR-1 prevents</strong> <strong>thrombin</strong> from<strong> activating platelets,</strong> thus <strong>reducing thrombotic events.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>: Prasugrel</strong> is a<strong> P2Y12 adenosine diphosphate receptor inhibitor,</strong> not a PAR-1 inhibitor.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Ticlopidine</strong> is also a <strong>P2Y12 adenosine diphosphate receptor inhibitor,</strong> used less commonly due to side effects.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Tirofiban</strong> is a<strong> glycoprotein IIb/IIIa </strong>inhibitor that<strong> blocks fibrinogen</strong> <strong>binding and platelet aggregation,</strong> not a PAR-1 antagonist.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Vorapaxar</strong> is a<strong> PAR-1 antagonist </strong>that<strong> inhibits platelet aggregation</strong> by<strong> preventing thrombin</strong> from <strong>binding to PAR-1 on platelets,</strong> offering a therapeutic approach in the<strong> prevention of thrombotic cardiovascular events. </strong></span></span></span></p>",
      "correct_choice_id": 32407,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8162,
      "choices": [
        {
          "id": 32616,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-thrombin III</span></span></span></p>"
        },
        {
          "id": 32617,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Protein C</span></span></span></p>"
        },
        {
          "id": 32618,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Protein S</span></span></span></p>"
        },
        {
          "id": 32619,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thrombomodulin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Heparin acts via activation of which of the following molecules?</span></span></span></p>",
      "unique_key": "Q1164278",
      "question_audio": null,
      "question_video": null,
      "map_id": 36284,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Anti-thrombin III</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Anti-thrombin III: Heparin </strong>acts by<strong> binding to and enhancing</strong> the <strong>activity of antithrombin III, </strong>a <strong>natural anticoagulant </strong>that <strong>inhibits the</strong> activity of <strong>clotting factors</strong> such as<strong> thrombin and factor Xa</strong>.<strong> Heparin</strong> <strong>accelerates</strong> the ability of <strong>antithrombin III </strong>to <strong>inhibit </strong>these <strong>clotting factors</strong>, resulting in the<strong> prevention and treatment of thrombotic events.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Protein C:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Protein C is a <strong>natural anticoagulant</strong> that is <strong>activated by thrombomodulin</strong>, a <strong>protein </strong>expressed on the<strong> surface of</strong> <strong>endothelial cells</strong>. <strong>Protein C inactivates factors V and VIII,</strong> which are<strong> involved</strong> in the <strong>clotting process</strong>. <strong>Heparin does not</strong> directly <strong>activate protein C.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Protein S:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Protein S is a <strong>cofactor for protein C, </strong>which <strong>enhances its activity.</strong> <strong>Heparin does not </strong>directly a<strong>ctivate protein S.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Thrombomodulin: </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Thrombomodulin </strong>is a <strong>protein </strong>expressed on the<strong> surface of endothelial cells</strong> that <strong>binds to</strong> and<strong> activates</strong> <strong>protein C</strong>. <strong>Heparin</strong> <strong>does not </strong>directly<strong> activate thrombomodulin.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Heparin </strong>acts by<strong> enhancing the activity of anti-thrombin III, </strong>which<strong> inhibits clotting factors</strong> such as <strong>thrombin and factor Xa.</strong></span></span></span></span></span></p>",
      "correct_choice_id": 32616,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8181,
      "choices": [
        {
          "id": 32692,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Protein C deficiency</span></span></span></p>"
        },
        {
          "id": 32693,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sickle cell anaemia</span></span></span></p>"
        },
        {
          "id": 32694,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Factor V leiden deficiency</span></span></span></p>"
        },
        {
          "id": 32695,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antithrombin 3 deficiency</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Warfarin induced skin necrosis is seen in. </span></span></span></p>",
      "unique_key": "Q9726448",
      "question_audio": null,
      "question_video": null,
      "map_id": 36287,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Protein C deficiency</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Warfarin-induced skin necrosis (WISN) </strong>is a <strong>rare </strong>complication of<strong> warfarin therapy. </strong>It is characterized by the development of painful <strong>skin lesions </strong>in <strong>patients taking warfarin</strong>. This condition is thought to be <strong>caused by a transient hypercoagulable state</strong> resulting from a <strong>rapid reduction in protein C levels</strong>, particularly in patients with <strong>underlying protein C deficiency </strong>or other risk factors. The <strong>lesions</strong> <strong>typically occur in areas</strong> with a<strong> high concentration of adipose tissue</strong>, such as the<strong> breasts, thighs, and buttocks</strong>. The initial symptoms of<strong> WISN</strong> include <strong>red or purple spots on the skin</strong> that can<strong> quickly progress to painful, necrotic lesions </strong>with a<strong> central blister or eschar.</strong> The<strong> diagnosis</strong> is usually made <strong>clinically </strong>based<strong> </strong>on the characteristic<strong> appearance of the lesions</strong> and the<strong> patient&#39;s history of warfarin therapy</strong>. The <strong>treatment of WISN </strong>involves <strong>stopping warfarin </strong>and <strong>initiating alternative anticoagulant therapy</strong>, such as<strong> heparin or low</strong> <strong>molecular weight heparin</strong>.<strong> </strong>In<strong> severe </strong>cases<strong>, surgical intervention</strong> may be necessary to <strong>remove the necrotic tissue</strong> and <strong>prevent</strong> <strong>further damage.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Sickle cell anaemia: </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sickle cell anaemia is <strong>not </strong>associated with<strong> warfarin-induced skin necrosis</strong>. <strong>Skin manifestations</strong> in sickle cell disease are typically related to<strong> vaso-occlusive crises</strong> and may include <strong>painful swelling of the hands and feet (dactylitis), leg ulcers,</strong> and<strong> skin infections.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Factor V Leiden deficiency: </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Factor V Leiden deficiency is <strong>not</strong> associated with <strong>warfarin-induced skin necrosis.</strong> <strong>Factor V</strong> <strong>Leiden mutation </strong>predisposes individuals to <strong>thrombosis </strong>by making them <strong>resistant to the anticoagulant effects </strong>of <strong>activated protein C.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Antithrombin 3 deficiency: </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antithrombin 3 deficiency is<strong> not</strong> associated with <strong>warfarin-induced skin necrosis. Antithrombin</strong> <strong>deficiency</strong> <strong>increases the risk of thrombosis </strong>due to<strong> impaired inhibition of coagulation factors</strong>, but it <strong>does not </strong>predispose individuals to <strong>warfarin-induced skin necrosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Warfarin-induced skin necrosis</strong> is primarily seen in patients with <strong>underlying protein C deficiency </strong>or other risk factors, characterized by the<strong> development of painful necrotic lesions,</strong> especially in areas with<strong> high adipose tissue concentration.</strong></span></span></span></p>",
      "correct_choice_id": 32692,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8244,
      "choices": [
        {
          "id": 32943,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aspirin</span></span></span></p>"
        },
        {
          "id": 32944,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clopidogrel </span></span></span></p>"
        },
        {
          "id": 32945,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Abciximab</span></span></span></p>"
        },
        {
          "id": 32946,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atopaxar</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Based on the mechanism of action shown in figure, Drug X is likely to be:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture10.jpg\" style=\"height:232px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q5701325",
      "question_audio": null,
      "question_video": null,
      "map_id": 36271,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Aspirin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Aspirin (acetylsalicylic acid) </strong>works by <strong>irreversibly inhibiting cyclooxygenase-1 (COX-1),</strong> which is an enzyme responsible for<strong> converting arachidonic acid to thromboxane A2 (TXA2). Thromboxane A2 is a potent vasoconstrictor and inducer of platelet aggregation. In the diagram, Drug X is shown to be inhibiting the pathway that leads to the production of TXA2, which aligns with the action of aspirin.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Clopidogrel: Clopidogrel is an ADP receptor inhibitor. It inhibits the P2Y12 receptor on the platelet surface, which is involved in ADP-induced platelet activation and aggregation. This mechanism is not consistent with the action of Drug X in the diagram.</span></span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Abciximab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Abciximab is a glycoprotein IIb/IIIa inhibitor. It binds to the glycoprotein IIb/IIIa receptor on the platelet surface, preventing fibrinogen binding and platelet aggregation. </strong>This <strong>action does not </strong>involve the<strong> COX pathway </strong>and therefore does <strong>not</strong> correspond to<strong> Drug X.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Atopaxar:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Atopaxar</strong> is a<strong> protease-activated receptor-1 (PAR-1) antagonist.</strong> It <strong>inhibits</strong> <strong>thrombin receptor signaling </strong>on <strong>platelets</strong>. Sinc<strong>e Drug X</strong> is<strong> shown acting</strong> on the<strong> COX pathway,</strong> <strong>Atopaxar</strong> is<strong> not </strong>the <strong>correct answer.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to<strong> identify antiplatelet drugs </strong>based on their <strong>mechanism of action</strong>, specifically recognizing the unique <strong>action of aspirin </strong>on the<strong> COX-1 enzyme </strong>leading to the<strong> inhibition of thromboxane A2 synthesis and subsequent platelet aggregation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antiplatelet Drugs</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture12.jpg\" style=\"height:521px; width:1000px\" /></span></span></strong></p>",
      "correct_choice_id": 32943,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8270,
      "choices": [
        {
          "id": 33047,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hirudin</span></span></span></p>"
        },
        {
          "id": 33048,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Argatroban</span></span></span></p>"
        },
        {
          "id": 33049,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bivalirudin</span></span></span></p>"
        },
        {
          "id": 33050,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dabigatran</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which among the following is an orally active anti thrombin drug?</span></span></span></p>",
      "unique_key": "Q4513329",
      "question_audio": null,
      "question_video": null,
      "map_id": 36280,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Dabigatran</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Dabigatran</strong> is an<strong> orally active anticoagulant </strong>that <strong>directly inhibits thrombin.</strong> It is a <strong>direct thrombin inhibitor (DTI)</strong> used to <strong>prevent</strong> <strong>stroke </strong>in patients with <strong>non-valvular atrial fibrillation</strong>, <strong>treat and prevent deep vein thrombosis and pulmonary embolism</strong>, and for other indications where <strong>anticoagulation is necessary.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hirudin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hirudin is a<strong> naturally occurring peptide</strong> from the <strong>medicinal leech</strong> that <strong>directly inhibits thrombin.</strong> However, it is <strong>not orally active.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Argatroban:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Argatroban is a<strong> synthetic direct thrombin inhibitor</strong>, but it is <strong>administered intravenously </strong>and not orally.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Bivalirudin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Bivalirudin is <strong>another direct thrombin inhibitor </strong>that is used<strong> intravenously,</strong> particularly during<strong> percutaneous</strong> <strong>coronary interventions</strong>, and is<strong> not taken orally.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to recognize the different <strong>anticoagulant drugs </strong>available for<strong> thrombin inhibition</strong> and to understand their <strong>routes of administration</strong>. Distinguishing between <strong>orally active and non-orally active anticoagulants</strong> is essential for <strong>proper patient</strong> <strong>management and treatment planning.</strong></span></span></p>",
      "correct_choice_id": 33050,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}